TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.71 USD
-0.01 (-0.58%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.68 -0.03 (-1.75%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for TherapeuticsMD, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 70 | 87 | 65 | 50 |
Cost Of Goods | 0 | 1 | 19 | 16 | 6 |
Gross Profit | 1 | 69 | 68 | 49 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 10 | 67 | 208 | 204 | 195 |
Income After Depreciation & Amortization | -9 | 1 | -140 | -156 | -151 |
Non-Operating Income | 1 | 0 | 0 | 1 | -8 |
Interest Expense | 0 | 0 | 33 | 29 | 17 |
Pretax Income | -8 | 1 | -172 | -184 | -176 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | 1 | -172 | -184 | -176 |
Extras & Discontinued Operations | -3 | 111 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | 112 | -172 | -184 | -176 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | 2 | -136 | -149 | -149 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 4 | 6 | 2 |
Income After Depreciation & Amortization | -9 | 1 | -140 | -156 | -151 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.44 | 9.37 | 7.96 | 4.93 | 4.93 |
Diluted EPS Before Non-Recurring Items | -0.74 | -13.46 | -21.00 | -34.00 | -34.00 |
Diluted Net EPS (GAAP) | -0.98 | 11.96 | -21.50 | -33.50 | -36.00 |
Fiscal Year end for TherapeuticsMD, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.23 | 0.31 | 0.50 | -0.05 | 0.44 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.23 | 0.31 | 0.50 | -0.05 | 0.44 |
SG&A, R&D, and Dept/Amort Expenses | 2.67 | 1.45 | 2.12 | 1.72 | 2.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.44 | -1.14 | -1.62 | -1.77 | -2.47 |
Non-Operating Income | 1.40 | 0.33 | -0.09 | 0.36 | 0.10 |
Interest Expense | 0.01 | 0.00 | -0.12 | 0.02 | 0.05 |
Pretax Income | -1.05 | -0.81 | -1.58 | -1.43 | -2.41 |
Income Taxes | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.05 | -0.81 | -1.54 | -1.43 | -2.41 |
Extras & Discontinued Operations | -0.04 | 0.08 | 0.66 | -1.94 | 0.00 |
Net Income (GAAP) | -1.09 | -0.73 | -0.88 | -3.38 | -2.41 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 11.53 | 11.53 | NA | 10.70 | 10.22 |
Diluted EPS Before Non-Recurring Items | -0.09 | -0.07 | NA | -0.13 | -0.24 |
Diluted Net EPS (GAAP) | -0.09 | -0.06 | -0.05 | -0.32 | -0.24 |